Company: WHWK
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001628280-25-020311
Chunk: 47

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 47
---
”), and (iii) 1,027,510 shares of common stock subject to Pre-Funded Warrants purchased in the PIPE Financing by the Averill Funds. The beneficial ownership shown above excludes an additional 2,551,348 shares of common stock subject to Pre-Funded Warrants purchased in the PIPE Financing by the Averill Funds. The Pre-Funded Warrants may not be exercised to the extent such exercise would cause the Averill Funds, together with their affiliates, to beneficially own in excess of 9.99% of the number of shares of our common stock outstanding immediately after giving effect to such exercise. Suvretta Capital Management, LLC is the investment manager of the Averill Funds. Aaron Cowen is a control person of Suvretta Capital Management, LLC and as such may be deemed to beneficially own these shares. The principal business address of Suvretta Capital Management, LLC is 540 Madison Avenue, 7th Floor, New York, NY 10022.

(3) Consists of 4,166,000 shares of common stock purchased in the PIPE Financing by OrbiMed Genesis Master Fund, L.P. (“Genesis”). OrbiMed Genesis GP LLC (“Genesis GP”) is the general partner of Genesis. OrbiMed Advisors is the managing member of Genesis GP. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis, except to the extent of its or his pecuniary interest therein if any. The address for each of the entities and individuals above is c/o OrbiMed Advisors LLC, 601 Lexington Avenue, 54th Floor, New York, New York.

(4) Consists of (i) the following shares of common stock purchased in the PIPE Financing: (a) 1,959,162 shares of common stock purchased by EcoR1 Capital Fund Qualified, L.P. (“Qualified Fund”) and (b) 122,838 shares of common stock purchased by EcoR1 Capital Fund, L.P. (“Capital Fund”, and together with Qualified Fund, the “EcoR1 Capital Funds”); and, (ii) based solely on a Schedule G filed with the SEC on August 23, 2025 (y) 1,736,015 shares of common stock that were previously held by Qualified Fund and (z)